Enbrel DTC Campaign Should Restore Growth In Psoriasis Market, Amgen Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The company had been sponsoring a disease awareness program while working to bring a branded spot back on the air after an FDA warning letter targeted an initial ad.
You may also be interested in...
Enbrel TV Ad Highlighting "Breakthrough Therapy" Draws FDA Warning Letter
Center for Drug Evaluation & Research ad review division says Amgen's commercial overstates the TNF-inhibitor's effectiveness, fails to communicate the limitations of the indication and minimizes risk. Amgen pulls the commercial from its media schedule in the wake of the agency's letter.
Amgen Enbrel Clears FDA For Psoriasis Supplemental Indication; Detailing Begins Immediately
The company calls on 3,500 dermatologists for its psoriatic arthritis indication; Amgen hopes to increase promotion to 9,000 dermatolgists.
Pink Sheet Podcast: Relyvrio And Public Promises, Allergy Biomarker Adcomms, PMDA In The USA
Pink Sheet reporters and editor discuss the implications of Amylyx following through on its pledge to remove Relyvrio from the market after its trial failed, an FDA idea to bring potential biomarkers for promising allergy and asthma treatments to advisory committees, and Japan’s PMDA opening an office in Washington D.C.